Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS011
MIFTS: 56

Plasmacytoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Plasmacytoma

About this section

MalaCards integrated aliases for Plasmacytoma:

Name: Plasmacytoma 12 52 58 54 43 15 17 71
Solitary Plasmacytoma 12 52 58 32
Solitary Osseous Plasmacytoma 71
Plasmacytoma - Category 71
Myeloma - Solitary 12
Myeloma, Solitary 12
Solitary Myeloma 12

Characteristics:

Orphanet epidemiological data:

58
plasmacytoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Blood diseases Immune diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:3721
MeSH 43 D010954
NCIt 49 C9349
SNOMED-CT 67 10639003 415112005
ICD10 32 C90.3
MESH via Orphanet 44 D010954
ICD10 via Orphanet 33 C90.2 C90.3
UMLS via Orphanet 72 C0032131
Orphanet 58 ORPHA86855
UMLS 71 C0032131 C0272256 C1532560
Sources

Summaries for Plasmacytoma

About this section
NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 86855 Definition Plasmacytoma is a localized mass of neoplastic monoclonal plasma cells that represents approximately 5% of all plasma cell neoplasms . There are two separate entities: primary plasmacytoma of the bone and extramedullary plasmacytoma of the soft tissues . Of the extramedullary plasmacytomas, 80% occur in the head and neck, usually in the upper respiratory tract. The median age at diagnosis is 50 years and the male to female ratio is 3:1. Long-term survival is possible following local radiotherapy, particularly for soft tissue presentations. Visit the Orphanet disease page for more resources.

MalaCards based summary : Plasmacytoma, also known as solitary plasmacytoma, is related to solitary osseous plasmacytoma and extramedullary plasmacytoma, and has symptoms including bone pain An important gene associated with Plasmacytoma is PVT1 (Pvt1 Oncogene), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Heptavalent Pneumococcal Conjugate Vaccine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include bone, b cells and t cells, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 74 Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within... more...

Sources

Related Diseases for Plasmacytoma

About this section

Diseases related to Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 594)
# Related Disease Score Top Affiliating Genes
1 solitary osseous plasmacytoma 34.3 NCAM1 CD79A CD38 B2M
2 extramedullary plasmacytoma 33.7 NCAM1 IRF4 IL6 CD79A CD38 CCND1
3 plasmablastic lymphoma 32.6 PTPRC PRDM1 MYC CD38
4 amyloidosis 31.3 IL6 IGKC CCND1 B2M
5 plasma cell neoplasm 31.3 PVT1 PTPRC PAX5 NCAM1 MYC IRF4
6 post-transplant lymphoproliferative disease 30.9 IL6 B2M
7 myeloma, multiple 30.8 PVT1 PTPRC PRDM1 PAX5 NCAM1 MYC
8 sarcoma 30.7 PTPRC MYC IL6ST IL6 CCND1
9 osteogenic sarcoma 30.6 PVT1 MYC IL6 IL11
10 human herpesvirus 8 30.5 IL6ST IL6R IL6
11 castleman disease 30.5 PAX5 IL6ST IL6R IL6
12 plasma cell leukemia 30.5 NCAM1 MYC IRF4 IL6 CD38 CCND1
13 kaposi sarcoma 30.5 OSM MYC IL6ST IL6 CCND1
14 acquired immunodeficiency syndrome 30.4 MYC IL6 CD79A CD38 CCND1 B2M
15 epiglottis neoplasm 30.3 PTPRC CD79A
16 thrombocytosis 30.3 LIF IL6 IL11
17 glomeruloid hemangioma 30.2 PTPRC IL6
18 waldenstroem's macroglobulinemia 30.2 CD79A CD38 B2M
19 non-secretory myeloma 30.2 NCAM1 CD38 B2M
20 immune deficiency disease 30.1 PTPRC IRF4 IL6 CD79A CD38 B2M
21 reticulosarcoma 30.0 PTPRC PAX5 MYC B2M
22 t-cell lymphoblastic leukemia/lymphoma 30.0 PTPRC MYC IRF4 CCND1
23 lymphoma, hodgkin, classic 30.0 PVT1 PTPRC PAX5 IRF4
24 suppression of tumorigenicity 12 30.0 PTPRC NCAM1 MYC IL6 CCND1
25 mediastinal malignant lymphoma 30.0 PAX5 CD79A
26 leukemia, chronic myeloid 30.0 PTPRC MYC IRF4 IL11 CD38 CCND1
27 blood protein disease 30.0 NCAM1 MYC IL6 CD38 B2M
28 marginal zone b-cell lymphoma 30.0 PAX5 IRF4 CD79A CD38 CCND1
29 monoclonal gammopathy of uncertain significance 29.9 PTPRC NCAM1 MYC IRF4 IL6 CD38
30 inflammatory bowel disease 29.9 PTPRC MYC IL6ST IL6R IL6 IL11
31 lymphoblastic lymphoma 29.9 PTPRC PAX5 MYC
32 richter's syndrome 29.9 MYC IRF4 CD38
33 acute promyelocytic leukemia 29.8 PVT1 PTPRC NCAM1 MYC IL6 CCND1
34 monoclonal paraproteinemia 29.8 PRDM1 PAX5 NCAM1 CD79A
35 b-cell lymphoma 29.8 PVT1 PTPRC PRDM1 PAX5 MYC IRF4
36 neuroendocrine carcinoma 29.7 PTPRC PAX5 NCAM1
37 lymphatic system disease 29.6 PTPRC MYC IRF4 CD79A CCND1
38 peripheral t-cell lymphoma 29.6 PTPRC PAX5 NCAM1 CD38 CCND1
39 lymphoma 29.6 PVT1 PTPRC PRDM1 PAX5 MYC IRF4
40 lymphoma, mucosa-associated lymphoid type 29.6 PTPRC PAX5 MYC IRF4 IGKC CD79A
41 alpha chain disease 29.5 CD79A CCND1
42 lymphoplasmacytic lymphoma 29.5 PTPRC PAX5 IRF4 CCND1
43 myeloid sarcoma 29.5 PTPRC PAX5 NCAM1 IRF4 CD79A
44 bone lymphoma 29.5 PTPRC PAX5 IRF4 CD79A
45 follicular lymphoma 29.5 PAX5 MYC IRF4 CCND1
46 leukemia, acute myeloid 29.5 PTPRC PAX5 NCAM1 MYC IL6 CD79A
47 burkitt lymphoma 29.4 PVT1 PRDM1 PAX5 MYC IRF4 IL6R
48 multicentric castleman disease 29.3 PAX5 IRF4 IL6 CD79A CD38
49 mantle cell lymphoma 29.0 PTPRC PRDM1 PAX5 MYC IL6 CCND1
50 leukemia, chronic lymphocytic 28.9 PTPRC PAX5 NCAM1 MYC IRF4 IL6

Graphical network of the top 20 diseases related to Plasmacytoma:



Diseases related to Plasmacytoma
Sources

Symptoms & Phenotypes for Plasmacytoma

About this section

UMLS symptoms related to Plasmacytoma:


bone pain

GenomeRNAi Phenotypes related to Plasmacytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCND1 CD79A EBF1 IL6R IL6ST MYC

MGI Mouse Phenotypes related to Plasmacytoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 B2M CCND1 CD38 CD79A EBF1 IL6
2 hematopoietic system MP:0005397 10.31 B2M CCND1 CD38 CD79A EBF1 IL6
3 homeostasis/metabolism MP:0005376 10.25 B2M CCND1 CD38 CD79A IL6 IL6R
4 immune system MP:0005387 10.24 B2M CCND1 CD38 CD79A EBF1 IL6
5 growth/size/body region MP:0005378 10.23 B2M CCND1 EBF1 IL6 IL6R IL6ST
6 endocrine/exocrine gland MP:0005379 10.18 B2M CCND1 CD38 IL6 IL6R IL6ST
7 integument MP:0010771 9.97 B2M CCND1 EBF1 IL6 IL6ST LIF
8 mortality/aging MP:0010768 9.97 B2M CCND1 CD79A EBF1 IL6 IL6R
9 liver/biliary system MP:0005370 9.96 B2M CD79A EBF1 IL6 IL6R IL6ST
10 neoplasm MP:0002006 9.7 B2M CCND1 CD79A IL6 IL6R IL6ST
11 nervous system MP:0003631 9.44 B2M CCND1 CD79A EBF1 IL6 IL6R
Sources

Drugs & Therapeutics for Plasmacytoma

About this section

Drugs for Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 289)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Zoledronic Acid Approved Phase 3 118072-93-8 68740
6
Melphalan Approved Phase 3 148-82-3 460612 4053
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
10
Idarubicin Approved Phase 3 58957-92-9 42890
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
12
deoxycholic acid Approved Phase 3 83-44-3 222528
13
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
14
Pamidronate Approved Phase 3 40391-99-9 4674
15
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
16
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
19
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
20
Ixazomib Approved, Investigational Phase 3 1072833-77-2
21
Daratumumab Approved Phase 3 945721-28-8
22
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
23
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
24
Glutaral Experimental Phase 3 111-30-8 3485
25
Oblimersen Experimental, Investigational Phase 3 190977-41-4
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Angiogenesis Inhibitors Phase 3
28 Antineoplastic Agents, Hormonal Phase 3
29 Antiemetics Phase 3
30 Gastrointestinal Agents Phase 3
31 Neurotransmitter Agents Phase 3
32 Trace Elements Phase 3
33 Nutrients Phase 3
34 Micronutrients Phase 3
35 interferons Phase 3
36 Antiviral Agents Phase 3
37 Interferon-alpha Phase 3
38 Ferric Oxide, Saccharated Phase 3
39 Dextrans Phase 3
40 Plasma Substitutes Phase 3
41 Iron-Dextran Complex Phase 3
42 Blood Substitutes Phase 3
43 Anesthetics, Dissociative Phase 3
44
Liposomal doxorubicin Phase 3 31703
45 Cola Phase 3
46 Tubulin Modulators Phase 3
47 Antimitotic Agents Phase 3
48 Hematinics Phase 3
49 Epoetin alfa Phase 3 113427-24-0
50 Amebicides Phase 3

Interventional clinical trials:

(show top 50) (show all 266)
# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
2 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
3 Study of Cyclophosphamide，Liposome Doxorubicin Dexamethasone（CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
4 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
5 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
6 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
7 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
8 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
9 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
11 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
12 A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer Completed NCT00058331 Phase 3
13 A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma Completed NCT00006232 Phase 3 dexamethasone;doxorubicin hydrochloride;idarubicin;vincristine sulfate
14 Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
15 A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
16 A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT00049673 Phase 3 prednisone;thalidomide
17 A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma Completed NCT00008229 Phase 3 melphalan
18 A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma Completed NCT00033332 Phase 3 dexamethasone;pamidronate disodium;thalidomide;zoledronic acid
19 Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00017602 Phase 3 dexamethasone
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
22 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
24 A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma Completed NCT00432458 Phase 3 Thalidomide;zoledronic acid
25 A Randomised Controlled Trial of Adjunctive Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Renal Failure [MERIT] MyEloma Renal Impairment Trial Completed NCT00416897 Phase 3 chemotherapy;dexamethasone
26 A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA Completed NCT00002878 Phase 3 dexamethasone;doxorubicin hydrochloride;valspodar;vincristine sulfate
27 Comparative Study of Dexamethasone vs Prednisone (Both in Combination With Melphalan) as Induction Therapy in Untreated Symptomatic Myeloma With an Additional Assessment of Dexamethasone vs no Additional Treatment as Maintenance Therapy in Non-Progressing Patients Completed NCT00002678 Phase 3 dexamethasone;melphalan;prednisone
28 Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients With Previously Untreated Multiple Myeloma Completed NCT00064038 Phase 3 dexamethasone;lenalidomide
29 Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL) Completed NCT00477971 Phase 3 dexamethasone;melphalan
30 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
31 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
32 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
33 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
34 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
35 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
36 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
37 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
38 Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Recruiting NCT02544308 Phase 3 Lenalidomide;Dexamethasone
39 Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Active, not recruiting NCT02516423 Phase 3 ixazomib;lenalidomide;dexamethasone;zoledronic acid
40 Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma Active, not recruiting NCT02136134 Phase 3 Daratumumab;VELCADE (Bortezomib);Dexamethasone
41 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
42 Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma Unknown status NCT00017433 Phase 2 arsenic trioxide
43 A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients Unknown status NCT00438841 Phase 2 bortezomib;cyclophosphamide;dexamethasone;thalidomide
44 CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma Unknown status NCT00017069 Phase 2 arsenic trioxide;dexamethasone
45 A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM) Unknown status NCT00742404 Phase 2 bortezomib;dexamethasone;pegylated liposomal doxorubicin hydrochloride
46 Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy Unknown status NCT00389701 Phase 2 bortezomib;dexamethasone
47 Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma Unknown status NCT00334932 Phase 1, Phase 2 bortezomib;melphalan;pegylated liposomal doxorubicin hydrochloride
48 A Phase II Study of High Dose Late Intensification Therapy in Patients With Chemotherapy Sensitive Multiple Myeloma Unknown status NCT00004903 Phase 2 cisplatin;cyclophosphamide;cytarabine;etoposide;melphalan
49 A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM) Unknown status NCT00526734 Phase 2 melphalan
50 A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma Unknown status NCT00637767 Phase 2 melphalan

Search NIH Clinical Center for Plasmacytoma

Cochrane evidence based reviews: plasmacytoma

Sources

Genetic Tests for Plasmacytoma

About this section
Sources

Anatomical Context for Plasmacytoma

About this section

MalaCards organs/tissues related to Plasmacytoma:

40
Bone, B Cells, T Cells, Bone Marrow, Thyroid, Breast, Lung
Sources

Publications for Plasmacytoma

About this section

Articles related to Plasmacytoma:

(show top 50) (show all 5671)
# Title Authors PMID Year
1
IL-6: from its discovery to clinical applications. 61 54
20410258 2010
2
Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs. 61 54
20404277 2010
3
IL-6 and MYC collaborate in plasma cell tumor formation in mice. 61 54
20018915 2010
4
Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. 54 61
19549820 2009
5
The 'zinc knuckle' motif of Early B cell Factor is required for transcriptional activation of B cell-specific genes. 54 61
18606452 2008
6
Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. 54 61
18648000 2008
7
Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. 54 61
18089822 2007
8
Identification of ERdj3 and OBF-1/BOB-1/OCA-B as direct targets of XBP-1 during plasma cell differentiation. 61 54
17709512 2007
9
c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. 54 61
17710161 2007
10
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. 54 61
17363561 2007
11
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. 54 61
17119059 2006
12
Myc translocations in B cell and plasma cell neoplasms. 54 61
16815105 2006
13
Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. 61 54
15751044 2005
14
[Expression of B cell-specific activator protein in lymphomas]. 54 61
16185503 2005
15
Up-date on solitary plasmacytoma and its main differences with multiple myeloma. 54 61
15812350 2005
16
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. 61 54
15735016 2005
17
RT-PCR analysis of RNA extracted from Bouin-fixed and paraffin-embedded lymphoid tissues. 61 54
15507667 2004
18
Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription. 61 54
15361869 2004
19
Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. 61 54
12612069 2003
20
The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. 61 54
12360049 2002
21
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells. 54 61
12685844 2002
22
MEK inhibitor U0126 interferes with immunofluorescence analysis of apoptotic cell death. 54 61
12210141 2002
23
Bob1 (OCA-B/OBF-1) differential transactivation of the B cell-specific B29 (Ig beta) and mb-1 (Ig alpha) promoters. 61 54
11907094 2002
24
IL-6 transgenic mouse model for extraosseous plasmacytoma. 54 61
11805288 2002
25
IL-11: insights in asthma from overexpression transgenic modeling. 61 54
11590369 2001
26
Unique function for carboxyl-terminal domain of Oct-2 in Ig-secreting cells. 54 61
11591767 2001
27
No involvement of Erk/MAP kinases in IL-6-induced proliferation of a B cell hybridoma cell line. 61 54
11556393 2001
28
Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. 61 54
11170286 2001
29
Localized amyloidosis and extramedullary plasmacytoma involving the larynx of a child. 61 54
11172308 2001
30
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. 54 61
11118064 2000
31
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. 54 61
11090073 2000
32
Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc. 61 54
10865979 2000
33
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. 61 54
10618400 2000
34
Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes. 54 61
10570182 1999
35
Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid. 61 54
10499534 1999
36
Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. 54 61
10500217 1999
37
Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas. 54 61
10535253 1999
38
Hematopoietic differentiation activity of a recombinant human interleukin-6 (IL-6) isoform resulting from alternatively spliced deletion of the second exon. 61 54
10398309 1999
39
Castleman's disease. 54 61
10655569 1999
40
Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. 61 54
9661903 1998
41
Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. 54 61
9459615 1997
42
Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma. 54 61
9284811 1997
43
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. 54 61
9284817 1997
44
Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. 61 54
9110979 1997
45
Concomitant downregulation of IgH 3' enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of translocated c-myc. 54 61
9188842 1997
46
Ig/myc translocations of the plasmacytoma-prone BALB/c strain occur independently of the genetic and parental origin of the affected chromosomes 6, 12, and 15. 54 61
8946197 1996
47
Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain. 54 61
8911151 1996
48
Early B-cell factor (EBF) down-regulates immunoglobulin heavy chain intron enhancer function in a plasmacytoma cell line. 61 54
8693297 1996
49
Multiple cytokines inhibit interleukin-6-dependent murine hybridoma/plasmacytoma proliferation. 61 54
8599834 1996
50
Production of interleukin-6 by human mast cells and basophilic cells. 61 54
8592085 1996
Sources

Variations for Plasmacytoma

About this section
Sources

Expression for Plasmacytoma

About this section
Search GEO for disease gene expression data for Plasmacytoma.
Sources

Pathways for Plasmacytoma

About this section

Pathways related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.93 PTPRC OSM NCAM1 MYC LIF IRF4
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.22 OSM NCAM1 MYC LIF IRF4 IL6ST
3
Human cytomegalovirus infection 36
Show member pathways
 12.88 MYC IL6ST IL6R IL6 CCND1 B2M
4
Pathways in cancer 36
12.77 MYC IL6ST IL6R IL6 CCND1
5
Th17 cell differentiation 36
Show member pathways
 12.53 MYC IRF4 IL6ST IL6R IL6
6
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.34 PTPRC MYC IRF4 CD79A
7
Human T-cell leukemia virus 1 infection 36
12.27 MYC IL6 CCND1 B2M
8
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.24 IL6ST IL6R IL6 CCND1
9
Colorectal Cancer Metastasis 63
12.14 MYC IL6R IL6 CCND1
10
JAK-STAT signaling pathway 36
Show member pathways
 12.01 PTPRC OSM MYC LIF IL6ST IL6R
11
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
12 NCAM1 MYC LIF IL6 IL11
12
Adipogenesis 1
11.98 OSM LIF IL6ST IL6 EBF1
13
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.86 PTPRC NCAM1 IL6 IL11 CD79A CD38
14
Hematopoietic cell lineage 36
11.85 IL6R IL6 IL11 CD38
15
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.83 PTPRC NCAM1 IL6 CD79A
16
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.81 IRF4 IL6ST IL6R IL6
17
Th17 Differentiation 64
Show member pathways
 11.79 IL6ST IL6R IL6
18
NF-kappaB Signaling 4
11.79 PTPRC PRDM1 PAX5 NCAM1 IRF4 IL6ST
19
IL-6 signaling pathway 1
Show member pathways
 11.77 PRDM1 MYC IL6ST IL6R IL6
20
Interleukin-4 and 13 signaling 65
11.76 OSM MYC LIF IRF4 IL6R IL6
21
Innate Lymphoid Cells Differentiation 64
11.72 PTPRC NCAM1 IRF4
22
C-MYB transcription factor network 1
11.7 PAX5 MYC CCND1
23
Dendritic Cells Developmental Lineage Pathway 64
11.67 PTPRC NCAM1 IRF4 IL6 CD38
24
Hepatitis C and Hepatocellular Carcinoma 1
11.5 MYC IL6R IL6 CCND1
25
Interleukin-6 family signaling 65
Show member pathways
 11.5 OSM LIF IL6ST IL6R IL6 IL11
26
Differentiation Pathway 1
11.47 IL6R IL6 IL11
27
RAF-independent MAPK1/3 activation 65
Show member pathways
 11.39 IL6ST IL6R IL6
28
IL-10 Pathway 63
11.3 MYC IL6 CCND1
29
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.28 LIF IL6 CCND1
30
Immune response_IL-6 signaling pathway 22
11.26 IL6ST IL6R IL6
31
Immune response_Oncostatin M signaling via JAK-Stat in human cells 22
10.97 OSM IL6ST CCND1
Sources

GO Terms for Plasmacytoma

About this section

Cellular components related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 OSM NCAM1 LIF IL6ST IL6R IL6
2 external side of plasma membrane GO:0009897 9.5 PTPRC NCAM1 IL6ST IL6R IGKC CD79A
3 ciliary neurotrophic factor receptor complex GO:0070110 9.16 IL6ST IL6R
4 interleukin-6 receptor complex GO:0005896 8.8 IL6ST IL6R IL6

Biological processes related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 PAX5 OSM MYC LIF IRF4 IL6
2 immune response GO:0006955 10.02 OSM LIF IL6 IGKC B2M
3 B cell receptor signaling pathway GO:0050853 9.81 PTPRC IGKC CD79A CD38
4 positive regulation of cell proliferation GO:0008284 9.81 OSM MYC LIF IL6ST IL6R IL6
5 B cell differentiation GO:0030183 9.79 PTPRC IL11 CD79A
6 interferon-gamma-mediated signaling pathway GO:0060333 9.78 NCAM1 IRF4 B2M
7 positive regulation of osteoblast differentiation GO:0045669 9.77 IL6ST IL6R IL6
8 positive regulation of T cell proliferation GO:0042102 9.77 PTPRC IL6ST IL6
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 MYC IL6R IL6
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.76 OSM LIF IL6 IL11
11 response to cytokine GO:0034097 9.75 IL6ST IL6R CD38
12 positive regulation of MAPK cascade GO:0043410 9.72 PTPRC OSM LIF IL6 IL11
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 OSM LIF IL6ST IL6R IL6
14 positive regulation of leukocyte chemotaxis GO:0002690 9.64 IL6R IL6
15 trophoblast giant cell differentiation GO:0060707 9.63 PRDM1 LIF
16 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.63 PTPRC IRF4
17 positive regulation of astrocyte differentiation GO:0048711 9.62 LIF IL6ST
18 interleukin-6-mediated signaling pathway GO:0070102 9.61 IL6ST IL6R IL6
19 positive regulation of acute inflammatory response GO:0002675 9.58 OSM IL6ST IL6
20 T-helper 17 cell lineage commitment GO:0072540 9.57 IRF4 IL6
21 re-entry into mitotic cell cycle GO:0000320 9.56 MYC CCND1
22 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.55 IL6ST IL6R
23 leukemia inhibitory factor signaling pathway GO:0048861 9.54 LIF IL6ST
24 negative regulation of hormone secretion GO:0046888 9.54 OSM LIF IL11
25 oncostatin-M-mediated signaling pathway GO:0038165 9.52 OSM IL6ST
26 hepatic immune response GO:0002384 9.48 IL6R IL6
27 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 PTPRC OSM LIF IL6R IL6 IL11
28 cytokine-mediated signaling pathway GO:0019221 9.28 OSM MYC LIF IRF4 IL6ST IL6R

Molecular functions related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.73 OSM LIF IL6 IL11
2 growth factor activity GO:0008083 9.71 OSM LIF IL6 IL11
3 ciliary neurotrophic factor receptor activity GO:0004897 9.37 IL6ST IL6R
4 interleukin-11 binding GO:0019970 9.32 IL6ST IL6R
5 interleukin-11 receptor activity GO:0004921 9.26 IL6ST IL6R
6 interleukin-6 binding GO:0019981 9.16 IL6ST IL6R
7 interleukin-6 receptor activity GO:0004915 8.96 IL6ST IL6R
8 interleukin-6 receptor binding GO:0005138 8.8 IL6ST IL6R IL6
Sources

Sources for Plasmacytoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....